Literature DB >> 8836799

Coagulation inhibitors and fibrinolytic parameters in patients on peritoneal dialysis and haemodialysis.

J Alwakeel1, A M Gader, S Hurieb, A K al-Momen, A Mitwalli, H Abu Aisha.   

Abstract

Coagulation inhibitors and fibrinolytic parameters were studied in twelve patients on continuous ambulatory peritoneal dialysis (CAPD) and ten patients on haemodialysis (HD). Patients on CAPD exhibited higher levels of ATIII and proteins C and S than those on HD. No significant differences were noted in tPA and PAI levels. Both groups of patients showed higher levels of tPA than controls. Besides, patients on HD had significantly lower levels of ATIII and protein C than controls. PAI levels in both patient groups were similar to those of the controls, but tPA levels were higher in patients than in controls. These results indicate that HD is associated with marked diminution in the circulating levels of coagulation inhibitors. This is in contrast to CAPD patients who showed elevated levels of these inhibitors, despite their significant loss in the dialysate. The finding of enhanced fibrinolysis in both patient groups may be a natural protective mechanism against the development of a thrombotic tendency.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8836799     DOI: 10.1007/bf02550871

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  21 in total

1.  Coagulation cascade, fibrinolytic system, antithrombin III, protein C and protein S in patients maintained on continuous ambulatory peritoneal dialysis.

Authors:  N D Vaziri; G M Shah; R L Winer; E Gonzales; B Patel; S Alikhani; Q X Nguyen; J Yamamoto
Journal:  Thromb Res       Date:  1989-01-15       Impact factor: 3.944

2.  Effect of hemodialysis on protein C levels.

Authors:  A Alegre; V Vicente; R Gonzalez; I Alberca
Journal:  Nephron       Date:  1987       Impact factor: 2.847

3.  Coagulation abnormalities in chronic peritoneal dialysis.

Authors:  C L Jones; M Andrew; A Eddy; M O'Neil; N I Shalom; J W Balfe
Journal:  Pediatr Nephrol       Date:  1990-03       Impact factor: 3.714

Review 4.  Peritoneal dialysis and loss of proteins: a review.

Authors:  J T Dulaney; F E Hatch
Journal:  Kidney Int       Date:  1984-09       Impact factor: 10.612

5.  Plasma levels and loss of antithrombin III in chronic ambulatory peritoneal dialysis and nephrotic patients.

Authors:  R Mori; L Triolo; V De Stefano; B P Giusti; P De Sole; G Leone
Journal:  Nephron       Date:  1988       Impact factor: 2.847

6.  Bleeding in renal failure: altered platelet function in chronic uraemia only partially corrected by haemodialysis.

Authors:  G Remuzzi; M Livio; G Marchiaro; G Mecca; G de Gaetano
Journal:  Nephron       Date:  1978       Impact factor: 2.847

7.  Antithrombin III and heparin cofactor II in patients with chronic renal failure undergoing regular hemodialysis.

Authors:  P Toulon; C Jacquot; L Capron; M O Frydman; D Vignon; M Aiach
Journal:  Thromb Haemost       Date:  1987-06-03       Impact factor: 5.249

8.  Protein C assays in uremia.

Authors:  P J Sørensen; F Knudsen; A H Nielsen; J Dyerberg
Journal:  Thromb Res       Date:  1989-05-15       Impact factor: 3.944

9.  Haemostatic effects of recombinant human erythropoietin in chronic haemodialysis patients.

Authors:  C van Geet; D Hauglustaine; L Verresen; M Vanrusselt; J Vermylen
Journal:  Thromb Haemost       Date:  1989-02-28       Impact factor: 5.249

10.  Antithrombin III loss in patients with nephrotic syndrome or receiving continuous ambulatory peritoneal dialysis. Evidence of inactive antithrombin III in urine of patients with nephrotic syndrome.

Authors:  V De Stefano; L Triolo; D De Martini; R Ferrelli; R Mori; G Leone
Journal:  J Lab Clin Med       Date:  1987-05
View more
  1 in total

1.  Protein Z and natural anticoagulants in children on peritoneal dialysis and hemodialysis.

Authors:  Kenan Bek; Ozan Ozkaya; Tunç Fişgin; Yüksel Aliyazicioğlu; M Sükrü Paksu; Tolga Ozgen; Davut Albayrak; Kemal Baysal
Journal:  Pediatr Nephrol       Date:  2006-11-24       Impact factor: 3.714

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.